VERESCA FOXC1 IHC Precision Oncology Test Phase 3 Trial: Data to be presented at ASCO 2024
The Californer/10279344

SAN DIEGO - Californer -- Onconostic Technologies-3N Diagnostics Group (OT/3NDx), a leader in precision oncology diagnostics, today announced that new breast cancer data will be highlighted in a Rapid Oral Abstract Session at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held on May 31 – June 4, 2024 at McCormick Place, Chicago, IL.

"We are excited to share the latest data on expanded clinical utility of the VERESCA^Ò FOXC1 IHC Precision Oncology Test with leading oncologists at the prestigious ASCO annual meeting," said Roberto Fagnani, PhD, President and COO of OT/3NDx. "Our relationship with Dr. Frederico Gustavo Rojo Todo and his esteemed team at GEICAM, the leading breast cancer research group in Spain, has been instrumental in rapidly advancing the technology and clinical acceptance of our precision oncology VERESCA test."

ASCO 2024 Rapid Oral Abstract Session

More on The Californer

• California: Governor Newsom calls out Trump's climate failure at the United Nations
• Fibromyalgia, It's Ayurvedic Prevention, Treatment and Cure, Dr. Abhay Kumar Pati, USA
• Home Assault Incident Involving Founder Oliver B. Mitchell III
• Last-Minute Travel Deals for Solo Senior Travelers Include No Single Supplement Opportunities
• Night Guardians Partners with Raven Donuts to Support Animal Rescue and Community Awareness

Title: Non-basal Subtype Defined by FOXC1 Expression as an Independent Predictor of Capecitabine Efficacy in the Triple Negative Breast Cancer GEICAM/2003-11_CIBOMA/2004-01 Trial.
Presenter: Frederico Gustavo Rojo Todo, MD, PhD, Hospital Universitario Fundación Jiménez Díaz; CIBERONC-ISCCIII; GEICAM Spanish Breast Cancer Group
Date: Friday, May 31, 2:45 p.m. CDT

About VERESCA^â FOXC1 IHC Precision Oncology Test

Tumor 'plasticity' triggers cancer metastasis leading to patient death. FOXC1 is a master regulatory gene of cancer plasticity and aggressiveness and, ultimately elevated patient death risk. OT/3NDx's patented VERESCA FOXC1 is an immunohistochemistry (IHC) tumor biopsy assay that identifies FOXC1 expression levels to guide personalized treatment selection for hormonal therapy, chemotherapy, and immunotherapy. It is the only test to identify those patients who are at heightened risk of suffering metastatic recurrence and will benefit from life-saving chemotherapy and targeted therapies. VERESCA has been validated in over 17,000 cancer patients. The test is CE Marked and commercially available to hospitals and oncologists in the European Union and countries recognizing CE Marking.

More on The Californer

• Port St. Lucie REALTOR® Irene Pernice Earns SFR® Certification
• AMR and UAS Take the Stage at WorldSkills Shanghai 2026
• City of Long Beach Opens Applications for Third Cohort of Long Beach Fire Corps Program
• Hyperglance Now Accepts Qualifying US Federal Micro-Purchases
• Cozmo AI Launches AI Workforce for Property and Casualty Claims

About OT/3NDx

OT/3NDx is leading precision oncology diagnostics with its versatile VERESCA FOXC1 test. We are dedicated to personalizing cancer diagnostics and therapy for patients, physicians and drug developers worldwide. Our patented technology enables multidisciplinary medical teams to identify previously unidentifiable aggressive cancers, personalize treatment selection, and identify which patients will benefit from targeted drug therapies.

For more information on OT/3NDx, please visit: www.onconostic.com or www.3ndx.com and follow us on LinkedIn.

Media Contact

Joleen Schultz
760-271-8150
joleen@joleenschultzassociates.com